Dr. Reddy's Forms Technology and Manufacturing Pact in Russia - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Dr. Reddy's Forms Technology and Manufacturing Pact in Russia

ePT--the Electronic Newsletter of Pharmaceutical Technology

Dr. Reddy’s Laboratories (Hyderabad, Andhra Pradesh, India) has entered into a technology transfer, manufacturing, and marketing agreement with R-Pharm (Moscow), a Russian pharmaceutical company. The agreement is based on a profit-sharing model and will entail licensing of manufacturing know-how of products by Dr. Reddy’s, local manufacturing of products in Russia, codevelopment of high-technology products, and knowledge sharing between the two companies.

R-Pharm was founded in 2001 and is involved in research and development (R&D), manufacturing of active ingredients and finished drug products, promotion, and distribution of pharmaceuticals used in hospitals and specialty care. It employs approximately 400 people and has 15 affiliates in the Russian Federation.

“We are excited about the collaboration as it helps us to deepen our engagement with Russia, one of our key markets,” said Satish Reddy, managing director and COO of Dr. Reddy’s in a Dec. 21, 2010, press release. “The agreement allows us to bring innovative medicines to the Russian people with active collaboration of a local pharmaceutical company, R-Pharm. It will also allow Dr. Reddy’s to import and market R-Pharm products in India according to agreed terms. The collaboration demonstrates our commitment to play a leading role in supporting the Russian government’s policy of Pharma 2020.”

Pharma 2020 is a plan by the Russian government to develop R&D and manufacturing of drugs by Russia’s domestic pharmaceutical sector. The plan seeks to elevate the market share of domestically produced generic and innovator drugs through increased investments in technology as well as R&D.

Dr. Reddy’s signed the agreement with R-Pharm at the India–Russia Forum on Trade and Investment in New Delhi on Dec. 20, 2010. The forum coincided with the visit of Russian President Dmitriy Medvedev to India.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here